• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Devices roar into the next decade

Devices roar into the next decade

June 3, 2019 By Sponsored Content

medical devices

Medical device investments skyrocketed in 2018, and these trends are continuing into 2019. The activity now will influence healthcare for the next decade.

This year, the medical device and diagnostic industry saw record-breaking increases in the investment scene. As noted by Silicon Valley Bank’s (SVB) analysis, Trends in Healthcare Investments and Exits 2019, investing in medtech is a hot trend. The annual report highlighted record-breaking trends in investments and fundraising in the biopharma, medical devices, and diagnostics sectors.

Meanwhile, Evaluate Medtech’s World Preview 2018, Outlook to 2024 examines what players, technologies, and environments will drive the industry into the future. The report predicts that the global medtech industry will grow at 5.6% per year (CAGR) between 2017 and 2024, culminating in global sales of $595 billion by 2024.

The pipelines for biopharma, medical devices, and diagnostics proved alluring to investors in 2018. Investments in 2018 for all areas surpassed that of 2017 by nearly 50%, according to the SVB analysis. And the trend seems poised to continue. Here, we’ll look at the current environment for device investing, and consider the elements that will drive future success in the industry.

Traditional investments, a return to M&A, plus big exits

In the device arena, investments grew 40% from 2017 to 2018. Devices in cardiovascular, oncology, ophthalmology and non-invasive monitoring all saw an increase in Series A deals and dollars. Series A investments in cardiovascular more than doubled, moving from $44 million among 9 companies in 2017 to $172 million among 14 companies in 2018.

Although Series A funding was up, later-stage investments saw even greater climbs. For example, late-stage investments in cardio also more than doubled, going from $389 million for 28 companies to $871 million for 34 companies.

Traditional VCs dominated device investments. Many of the dollars came post-FDA approval so that investors could see quick (and lucrative) returns. The value of exits was up at $4.8B across 19 deals.

For the first time, venture-backed device M&A total upfront payments eclipsed all other sectors, reaching $3.5 billion. At $190M, 2018 had the largest median upfront device payment since 2013.

Boston Scientific led M&A, acquiring seven venture-backed companies in 2018. Boston Scientific also announced it will buy BTG plc (a large public company). Medtronic acquired a small public company, Mazor. Both new acquirers, like Teleflex and LivaNova, and stalwarts like J&J continue to be active. Moreover, new acquirers, like Penumbra, Massimo, Avanos, and Siemens Healthineers, could emerge as they look to build their R&D pipeline.

Companies and technologies

In the cardiovascular sector, deals focused on assist devices and mitral valve repair.

Both oncology and ophthalmology saw investments that involved surgical robotics. Tumor visualization and precision drug delivery also boosted oncology device investments.

Investments in ophthalmology and neurology highlighted a focus on surgical robotics and targeted drug delivery. The biggest deals included four that were valued over $150 million in 2017 and 2018 involving RxSight, Ivantis, Sight Sciences, and Avedro.

California and Massachusetts are the hotbeds of the healthcare investment scene, with the combination of Northern and Southern California forming a juggernaut of healthcare investing. The state drew 78 investment deals at $1.961 billion and launched 30 Series A deals totaling $311 million in funding.

Regulatory paths open up, R&D surges

One of the most important factors in the growth of device investments is the new regulatory pathways opening up, according to Evaluate Medtech’s report. The FDA has repeatedly stated its determination to speed medical devices to market. The number of innovative products granted first-time premarket approval grew to 51 in 2017, up from 40 the year before. De Novo 510(k) pathway deals had successful exits and total deal values far exceeding those of traditional 510(k) and PMA deals.

The ramp-up of all products submitted to the FDA shows a high pace of innovation. That pace will require continued R&D streams as the industry moves into the next decade.

The medtech market’s R&D spend is set to increase by 4.5% each year, reaching $39 billion by 2024. From the Evaluate Medtech report, large companies will lead the way.

Medtronic will spend $2.7 billion by 2024, growing at 2.8% CAGR between 2017 and 2024. Becton Dickinson and Edwards Lifesciences are forecast to increase their annual R&D spend the most, growing at a CAGR of 8.4% and 8.3%, respectively. Edwards Lifesciences and bioMérieux are expected to invest substantially more in R&D as a percentage of their medtech sales than the other top 20 companies, with an R&D investment rate of nearly 16% in 2024.

One of the keys to ensuring the focus stays on R&D and developing products that meet FDA standards is to improve cost containment in other expenditures. Clinical trial management constitutes a significant share of resources. Companies that aim to improve R&D and prove the science behind it will want to explore programs such as electronic data capture (EDC).

For example, Smith and Nephew, which will be among the top ten medical device companies in sales over the next five years recently consolidated all of its global studies on the Medidata Rave Clinical Cloud.

Medidata can create a seamless data flow from EDC to clinical trial management system on a single platform. This simplifies trial oversight, providing clinical operations teams with easy access and visualization of data to understand enrollment and progress of a clinical trial.

Using Medidata’s platform, Smith & Nephew can grow its study portfolio faster by breaking down data silos, allowing teams to focus on oversight activities that are critical to the success of a trial.

Conclusion

The healthcare industry has been slowly building up steam, laying the groundwork for better products and processes, that lead with digital advances and cloud computing. In the last two years, the industry has come roaring into its own with exciting technologies that aim to revolutionize healthcare.

Strong focus on R&D, advance of new technologies, a supportive FDA, and attention to data capture and management have led to unprecedented investment in the future of devices and the role they will play for healthcare in the future.

Sponsored content by Medidata Solutions

Filed Under: Sponsored Content Tagged With: medicaldevices, Medidata Solutions

In case you missed it

  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive
  • MedTrace Pharma moves forward on 15 O-water imaging tech
  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system
  • Ambu replaces CEO with new leadership
  • Moderna’s first bivalent COVID-19 vaccine booster candidate shows promise
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
  • FDA clears Accelus’ Toro-L interbody fusion system
  • Teleflex’s UroLift cleared in China to treat BPH
  • Globus Medical announces first surgeries with Excelsius3D
  • Abbott reports positive data on heart valve therapies

RSS From Medical Design & Outsourcing

  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]
  • Google Health hires FDA’s chief digital health officer
    Former FDA Chief Digital Health Officer of Global Strategy and Innovation Bakul Patel has started a new job with Google after 13 years with the regulatory agency. Patel became senior director, global digital health strategy and regulatory for Google Health earlier this month, he said on LinkedIn. Patel recounted highlights of his “incredible journey since… […]
  • Expect more heart and lung failure years after COVID, Abbott’s heart failure CMO says
    Two years into the COVID-19 pandemic, we know more than ever about the SARS-CoV-2 virus and how quickly it moves to ravage the human body. What remains to be seen is how the virus — and perhaps more importantly, our immune system’s response to it — will affect the health of people long after infection,… […]
  • FDA moves forward with Voluntary Improvement Program to bolster medical device quality
    Kathryn Burke, Emergo Group The U.S. Food and Drug Administration has issued new draft guidance to establish a full-blown voluntary program for improving quality-related processes in medical device manufacturing following promising results of a pilot program. The FDA guidance stems from a pilot undertaken by the agency along with the Medical Device Innovation Consortium (MDIC) in 2018.… […]

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS